

Julie A Tucker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5324517/publications.pdf>

Version: 2024-02-01

44
papers

2,529
citations

201674

27
h-index

254184

43
g-index

44
all docs

44
docs citations

44
times ranked

3923
citing authors

#	ARTICLE	IF	CITATIONS
1	Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6513-6540.	6.4	3
2	Validation of ion mobility spectrometry \times mass spectrometry as a screening tool to identify type II kinase inhibitors of FGFR1 kinase. <i>Rapid Communications in Mass Spectrometry</i> , 2021, , e9130.	1.5	4
3	The thrombopoietin receptor: revisiting the master regulator of platelet production. <i>Platelets</i> , 2021, 32, 770-778.	2.3	23
4	An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF- κ B-Inducing Kinase. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10001-10018.	6.4	9
5	Recent Advances in Kinase Drug Discovery Part I: The Editors'™ Take. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7560.	4.1	1
6	Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors. <i>Nature Communications</i> , 2020, 11, 1383.	12.8	30
7	Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations. <i>Science</i> , 2020, 367, 643-652.	12.6	123
8	Small molecule ERK5 kinase inhibitors paradoxically activate ERK5 signalling: be careful what you wish for. <i>Biochemical Society Transactions</i> , 2020, 48, 1859-1875.	3.4	22
9	Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38 β and BRD4. <i>European Journal of Medicinal Chemistry</i> , 2019, 178, 530-543.	5.5	15
10	New Paradigms for the Mechanisms of Thrombopoietin Receptor Activation and Dysregulation By the JAK2V617F Mutation. <i>Blood</i> , 2019, 134, 2962-2962.	1.4	0
11	Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARC): Discovery and Optimization of Orally Bioavailable Quinazolinone Sulfonamides. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10767-10792.	6.4	23
12	Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer. <i>Oncotarget</i> , 2018, 9, 13139-13153.	1.8	25
13	Keep it together: restraints in crystallographic refinement of macromolecule \times ligand complexes. <i>Acta Crystallographica Section D: Structural Biology</i> , 2017, 73, 93-102.	2.3	19
14	Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH). <i>Oncotarget</i> , 2017, 8, 104478-104491.	1.8	27
15	First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARC) Inhibit DNA Repair with Differential Pharmacology to Olaparib. <i>ACS Chemical Biology</i> , 2016, 11, 3179-3190.	3.4	101
16	Discovery of a novel allosteric inhibitor-binding site in ERK5: comparison with the canonical kinase hinge ATP-binding site. <i>Acta Crystallographica Section D: Structural Biology</i> , 2016, 72, 682-693.	2.3	15
17	Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9. <i>MedChemComm</i> , 2016, 7, 1580-1586.	3.4	19
18	Small Molecule Binding Sites on the Ras:SOS Complex Can Be Exploited for Inhibition of Ras Activation. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2265-2274.	6.4	104

#	ARTICLE	IF	CITATIONS
19	Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase. <i>Nature Communications</i> , 2015, 6, 7877.	12.8	52
20	Structure Guided Lead Generation for <i>M. tuberculosis</i> Thymidylate Kinase (Mtb TMK): Discovery of 3-Cyanopyridone and 1,6-Naphthyridin-2-one as Potent Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 753-766.	6.4	40
21	Structural Insights into FGFR Kinase Isoform Selectivity: Diverse Binding Modes of AZD4547 and Ponatinib in Complex with FGFR1 and FGFR4. <i>Structure</i> , 2014, 22, 1764-1774.	3.3	81
22	FGFR1 Kinase Inhibitors: Close Regioisomers Adopt Divergent Binding Modes and Display Distinct Biophysical Signatures. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 166-171.	2.8	14
23	Thiazolopyridine Ureas as Novel Antitubercular Agents Acting through Inhibition of DNA Gyrase B. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8834-8848.	6.4	55
24	Aminopyrazinamides: Novel and Specific GyrB Inhibitors that Kill Replicating and Nonreplicating <i>Mycobacterium tuberculosis</i> . <i>ACS Chemical Biology</i> , 2013, 8, 519-523.	3.4	76
25	Discovery of Novel Potent and Highly Selective Glycogen Synthase Kinase-3 β (GSK3 β) Inhibitors for Alzheimer's Disease: Design, Synthesis, and Characterization of Pyrazines. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9107-9119.	6.4	126
26	Design and Synthesis of Novel Lactate Dehydrogenase A Inhibitors by Fragment-Based Lead Generation. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 3285-3306.	6.4	144
27	Structures of the Human Poly (ADP-Ribose) Glycohydrolase Catalytic Domain Confirm Catalytic Mechanism and Explain Inhibition by ADP-HPD Derivatives. <i>PLoS ONE</i> , 2012, 7, e50889.	2.5	46
28	Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKK μ kinases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2063-2069.	2.2	42
29	Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6670-6674.	2.2	32
30	Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4442-4446.	2.2	32
31	Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5487-5492.	2.2	28
32	The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 6369-6373.	2.2	41
33	How Tyrosine 15 Phosphorylation Inhibits the Activity of Cyclin-dependent Kinase 2-Cyclin A. <i>Journal of Biological Chemistry</i> , 2007, 282, 3173-3181.	3.4	85
34	Structure-based design of protein tyrosine phosphatase-1B inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 2503-2507.	2.2	68
35	Crystal Structure of Human Thymidine Phosphorylase in Complex with a Small Molecule Inhibitor. <i>Structure</i> , 2004, 12, 75-84.	3.3	82
36	Imidazo[1,2- <i>b</i>]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 2249-2252.	2.2	78

#	ARTICLE	IF	CITATIONS
37	Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-Bis anilino pyrimidines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 2955-2960.	2.2	94
38	Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 2961-2966.	2.2	61
39	Probing the ATP Ribose-Binding Domain of Cyclin-Dependent Kinases 1 and 2 with O6-Substituted Guanine Derivatives. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 3381-3393.	6.4	90
40	Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. <i>Nature Structural Biology</i> , 2002, 9, 745-749.	9.7	198
41	Cyclin-dependent kinases: inhibition and substrate recognition. <i>Current Opinion in Structural Biology</i> , 1999, 9, 738-744.	5.7	109
42	Quantitative Evaluation of Neurotensin Receptor Purification by Immobilized Metal Affinity Chromatography. <i>Protein Expression and Purification</i> , 1997, 11, 53-60.	1.3	66
43	Title is missing!. <i>Biotechnology Letters</i> , 1997, 19, 425-428.	2.2	26
44	Purification of a rat neurotensin receptor expressed in <i>Escherichia coli</i> . <i>Biochemical Journal</i> , 1996, 317, 891-899.	3.7	200